Sycona leads Azeria’s £32m financing round
The company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer.
21st November 2019
The company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer.
21st November 2019
The MSD blockbuster has been approved as monotherapy or as part of a chemotherapy combination.
21st November 2019
96.7% of men in the relugolix trial achieved sustained testosterone suppression to castrate levels.
20th November 2019
GSK’s formulation of the drug, Zantac, was recalled in the USA last month after the FDA found “unacceptable” levels of carcinogen in the medicine.
20th November 2019
The four-hour workshop will educate students aged seven to 13 on heart health.
20th November 2019
The money will go towards the development of the new “Spark Building”, which will provide interim lab and office accommodation whilst more permanent accommodation is developed nearby.
20th November 2019
The 2020 competition has welcomed a strong start to entry numbers since launching in September.
19th November 2019
The Phase II trial results are “impressive” and “encouraging”.
19th November 2019
76% of health leaders said in a survey that supporting and growing the NHS workforce should be a critical priority, ranking it highest.
19th November 2019
Co-administered with aspirin, Brilinta is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome.
19th November 2019
The Invokana trial will be completed virtually, with no in-person clinical visits required.
19th November 2019
The funding announcement coincides with the launch of Cancer Research UK’s “Right Now” campaign, which aims to show both the realities of the disease and the positive impact research and improved treatments can have on people’s lives.
18th November 2019
As of the approval, the treatment is expected to be available to patients in the coming weeks.
18th November 2019
The trial is the first with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction, with and without type II diabetes.
18th November 2019
The industry body hopes that the proceeding Government will “shape one of our country’s most valuable assets: an incredible pharmaceutical industry that employs tens of thousands and invests billions in research.”
18th November 2019